Medical Supply and Equipment Business Investment Opportunities in London

• Global consumer healthcare company focused on smoking harm reduction through patented, drug-free nicotine and tar reduction technology. • Core product is a liquid solution applied to cigarette filters that blocks up to 99% of tar and nicotine while allowing adult smokers to maintain their normal smoking ritual. • Targets adult smokers seeking harm reduction and gradual smoking cessation without prescription drugs or behavioural disruption. • Operates a scalable contract-manufacturing and distribution-led model with sales channels across OTC retail, pharmacies, government health programmes, and international distribution partnerships. • Built around proprietary technology with worldwide patents and trademarks protected until 20 years from now, creating long-term defensibility in the smoking cessation sector. • Regulatory clearances and ingredient approvals secured across major markets, including FDA-approved ingredients in the USA, NHS ethical clearance in the UK, TGA Australia, and approvals across 40+ countries. • Established international footprint with active or contracted distribution and government programmes across GCC countries, Africa, Australia, New Zealand, China, Japan, Singapore, Malaysia, Indonesia, Greece, and Cyprus. • Additional platform extensions planned for cigarette filter capsules, government smoking-reduction tenders, and solutions designed for the global hookah and shisha market. • Positioned to address the growing global smoking cessation and harm-reduction market estimated at over $25 billion, serving approximately 1.1 billion smokers worldwide. • Reports strong financial performance with EBITDA margins of approximately 40%, fully audited financial statements, and no bank borrowings. • Asset-light operating structure enables rapid scalability while maintaining strong profitability and international expansion flexibility. • Management has developed a long-term intellectual property monetisation strategy with an indicative IP valuation target of approximately $50 million in the next 6 years. • Business holds multiple international regulatory clearances, proprietary intellectual property protections, and audited financial compliance across key operating markets.

We are a London based manufacturer and supplier of dental implants. - We manufacture surgical devices which is used to replace missing teeth. - Our manufacturing capacity is around 150,000 dental implants per annum. - Have our distribution network in UAE, Saudi Arabia, Oman, Yemen, Taiwan, India. - Company is managed by highly qualified experts and professionals in the field of maxillary, prosthodontic and periodontal surgery. - Have completed the company set up and have an inventory worth GBP 200,000. We need funds to market our product worldwide. - We received a huge influx of clients this year which increased our revenue to an all-time high. The valuation is based on our own estimate.

We are a London based manufacturer and supplier of dental implants. - We manufacture surgical devices which is used to replace missing teeth. - Our manufacturing capacity is around 150,000 dental implants per annum. - Have our distribution network in UAE, Saudi Arabia, Oman, Yemen, Taiwan, India. - Company is managed by highly qualified experts and professionals in the field of maxillary, prosthodontic and periodontal surgery. - Have completed the company set up and have an inventory worth GBP 200,000. We need funds to market our product worldwide. - We received a huge influx of clients this year which increased our revenue to an all-time high. The valuation is based on our own estimate.